These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 36649259)
21. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. Zhang P; Zhang Y; Ji N Front Immunol; 2022; 13():927132. PubMed ID: 35874698 [TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
23. CAR-T cell therapy: current limitations and potential strategies. Sterner RC; Sterner RM Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268 [TBL] [Abstract][Full Text] [Related]
24. Neurological Complications of CAR T Cell Therapy. Landry K; Thomas AA Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727 [TBL] [Abstract][Full Text] [Related]
25. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy]. Hiramatsu H Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496 [TBL] [Abstract][Full Text] [Related]
26. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies. Matsueda S; Chodon T; Koya RC Adv Exp Med Biol; 2019; 1143():217-229. PubMed ID: 31338822 [TBL] [Abstract][Full Text] [Related]
28. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. Shen C; Zhang Z; Zhang Y Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182 [TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives. Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980 [TBL] [Abstract][Full Text] [Related]
30. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK Front Immunol; 2021; 12():670286. PubMed ID: 34135898 [TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S Front Immunol; 2018; 9():239. PubMed ID: 29515572 [TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
36. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Sun W; Jiang Z; Jiang W; Yang R Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307 [TBL] [Abstract][Full Text] [Related]
38. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Hill JA; Seo SK Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924 [TBL] [Abstract][Full Text] [Related]
39. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Wang L Curr Res Transl Med; 2022 Jan; 70(1):103320. PubMed ID: 34768218 [TBL] [Abstract][Full Text] [Related]